Patents by Inventor Jean-Marc Lapierre

Jean-Marc Lapierre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6838472
    Abstract: The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: January 4, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Michael Klaus, Jean-Marc Lapierre
  • Patent number: 6828337
    Abstract: This invention relates to new RAR selective retinoid agonists of formula I wherein the symbols are as defined in the specification to their pharmaceutically acceptable salts, individual isomers or to a racemic or non-racemic mixture; to pharmaceutical compositions containing them, and to methods for their use as therapeutic agents.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: December 7, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Paula Nanette Belloni, Michael Klaus, Jean-Marc Lapierre
  • Patent number: 6818652
    Abstract: The current invention provide novel heterocyclic retinoid compounds, methods of treating or preventing chronic obstructive pulmonary disease, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of these disorders and methods for delivering formulations of these retinoids to a mammal having these disorders.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: November 16, 2004
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Michael Klaus, Jean-Marc Lapierre
  • Patent number: 6777418
    Abstract: The current invention provide novel retinoid compounds and methods for their synthesis, methods of treating or preventing emphysema, cancer and dermatological disorders and pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders.
    Type: Grant
    Filed: October 1, 2001
    Date of Patent: August 17, 2004
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Jean-Marc Lapierre, David Mark Rotstein, Eric Brian Sjogren
  • Publication number: 20030176726
    Abstract: This invention relates to new RAR selective retinoid agonists of formula I 1
    Type: Application
    Filed: December 19, 2002
    Publication date: September 18, 2003
    Inventors: Paula Nanette Belloni, Michael Klaus, Jean-Marc Lapierre
  • Publication number: 20030158178
    Abstract: The current invention provide novel heterocyclic retinoid compounds, methods of treating or preventing chronic obstructive pulmonary disease, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of these disorders and methods for delivering formulations of these retinoids to a mammal having these disorders.
    Type: Application
    Filed: October 30, 2002
    Publication date: August 21, 2003
    Applicant: Syntex (U.S.A.) LLC
    Inventors: Michael Klaus, Jean-Marc Lapierre
  • Publication number: 20030158226
    Abstract: The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.
    Type: Application
    Filed: September 17, 2002
    Publication date: August 21, 2003
    Applicant: Roche Bioscience, a division of Syntex (U.S.A.) LLC
    Inventors: Paula Nanette Belloni, Denis John Kertesz, Michael Klaus, Jean-Marc Lapierre
  • Patent number: 6603012
    Abstract: New compounds containing bicyclic fused rings, one of which being a phenyl moiety connected by an aliphatic chain to a cycloalkyl or aryl moiety, and pharmaceutically active salts thereof are useful as RAR selective retinoid agonists. Furthermore, such retinoic acid receptor agonists, particularly retinoic acid receptor &ggr; (RAR&ggr;) selective agonists, are useful for the treatment of emphysema and associated pulmonary diseases, as well as for the therapy and prophylaxis of dermatological disorders, for the therapy and prophylaxis of malignant and premalignant epithelial lesions, tumors and precancerous changes of the mucous membrane in the mouth, tongue, larynx, esophagus, bladder, cervix and colon.
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: August 5, 2003
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Paula Nanette Belloni, Synese Jolidon, Michael Klaus, Jean-Marc Lapierre
  • Publication number: 20030125383
    Abstract: The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.
    Type: Application
    Filed: September 17, 2002
    Publication date: July 3, 2003
    Applicant: Roche Bioscience, a division of Syntex (U.S.A.) LLC
    Inventors: Michael Klaus, Jean-Marc Lapierre
  • Patent number: 6528677
    Abstract: This invention relates to new RAR selective retinoid agonists of formula I: wherein the symbols are as defined in the specification to their pharmaceutically acceptable salts, individual isomers or to a racemic or non-racemic mixture; to pharmaceutical compositions containing them, and to methods for their use as therapeutic agents.
    Type: Grant
    Filed: July 26, 2000
    Date of Patent: March 4, 2003
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Paula Nanette Belloni, Michael Klaus, Jean-Marc Lapierre
  • Publication number: 20020082265
    Abstract: The current invention provide novel retinoid compounds and methods for their synthesis, methods of treating or preventing emphysema, cancer and dermatological disorders and pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders.
    Type: Application
    Filed: October 1, 2001
    Publication date: June 27, 2002
    Inventors: Jean-Marc Lapierre, David Mark Rotstein, Eric Brian Sjogren
  • Patent number: 6403810
    Abstract: This invention relates to new retinoic acid receptor selective retinoid agonists, to pharmaceutical compositions containing such compounds, and to the use of such retinoic acid receptor agonists, particularly retinoic acid receptor &ggr; (RAR&ggr;) selective agonists, for the treatment of emphysema and related pulmonary diseases.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: June 11, 2002
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael Klaus, Jean-Marc Lapierre
  • Publication number: 20020026060
    Abstract: New compounds containing bicyclic fused rings, one of which being a phenyl moiety connected by an aliphatic chain to a cycloalkyl or aryl moiety, and pharmaceutically active salts thereof are useful as RAR selective retinoid agonists. Furthermore, such retinoic acid receptor agonists, particularly retinoic acid receptor &ggr; (RAR&ggr;) selective agonists, are useful for the treatment of emphysema and associated pulmonary diseases, as well as for the therapy and prophylaxis of dermatological disorders, for the therapy and prophylaxis of malignant and premalignant epithelial lesions, tumors and precancerous changes of the mucous membrane in the mouth, tongue, larynx, esophagus, bladder, cervix and colon.
    Type: Application
    Filed: April 23, 2001
    Publication date: February 28, 2002
    Inventors: Paula Nanette Belloni, Synese Jolidon, Michael Klaus, Jean-Marc Lapierre
  • Publication number: 20020019438
    Abstract: This invention relates to new retinoic acid receptor selective retinoid agonists, to pharmaceutical compositions containing such compounds, and to the use of such retinoic acid receptor agonists, particularly retinoic acid receptor &ggr; (RAR&ggr;) selective agonists, for the treatment of emphysema and related pulmonary diseases.
    Type: Application
    Filed: June 15, 2001
    Publication date: February 14, 2002
    Inventors: Michael Klaus, Jean-Marc Lapierre